

Inventors: Civelli and Lin
Serial No.: 09/932,161
Filed: August 17, 2001
Page 3

CURRENT STATUS OF ALL CLAIMS

1. Cancelled.

2. (Currently amended) A method of screening for a compound for promoting wakefulness in a mammal, comprising: The method of claim 1, wherein step (a) comprises

(a) contacting a PrRP receptor with one or more candidate compounds under conditions wherein PrRP promotes a predetermined PrRP receptor signal[[,]];

(b) identifying a compound that promotes said predetermined PrRP receptor signal; [[, and]]

(c) providing said compound, and

(d) determining the ability of said compound to promote wakefulness.

3. (Currently amended) The method of claim 2, wherein said predetermined PrRP receptor signal is selected from the group consisting of calcium ion mobilization and arachadonic acid metabolite release.

4. (Original) The method of claim 2, wherein said PrRP receptor is GPR10.

Inventors: Civelli and Lin
Serial No.: 09/932,161
Filed: August 17, 2001
Page 4

5. (Original) The method of claim 2, wherein said PrRP receptor is contacted with greater than about 100 candidate compounds.

6. (Original) The method of claim 2, wherein said PrRP receptor is contacted with greater than about 10^5 candidate compounds.

7. (Currently amended) A method of screening for a compound for promoting wakefulness in a mammal, comprising: The method of claim 1, wherein step (a) comprises

(a) contacting a PrRP receptor with one or more candidate compounds under conditions wherein PrRP binds to said PrRP receptor [[,]];

(b) identifying a compound that binds to said PrRP receptor; [[, and]]

(c) providing said compound, and

(d) determining the ability of said compound to promote wakefulness.

8. (Original) The method of claim 7, wherein said PrRP receptor is GPR10.

Inventors: Civelli and Lin
Serial No.: 09/932,161
Filed: August 17, 2001
Page 5

9. (Original) The method of claim 7, wherein said PrRP receptor is contacted with greater than about 100 candidate compounds.

10. (Original) The method of claim 7, wherein said PrRP receptor is contacted with greater than about 10^5 candidate compounds.

11. (Previously amended) A method of screening for a compound for promoting wakefulness in a mammal, comprising:

(a) contacting a PrRP receptor with one or more candidate compounds under conditions wherein PrRP promotes interaction of PrRP receptor with an AMPA receptor associated protein;

(b) identifying a compound that promotes said interaction;

(c) providing said compound, and

(d) determining the ability of said compound to promote wakefulness.

12. (Original) The method of claim 11, wherein said AMPA receptor associated protein is selected from the group consisting of GRIP, GRIP2 and PICK1.

Inventors: Civelli and Lin
Serial No.: 09/932,161
Filed: August 17, 2001
Page 6

13. (Currently amended) The method of claim ~~[[1]]~~ 2, wherein the ability of said compound to promote wakefulness is determined by a method selected from the group consisting of EEG measurement, EMG measurement and wake time measurement.

14. (Currently amended) The method of claim ~~[[1]]~~ 2, wherein the ability of said compound to promote wakefulness is determined by administering said compound to a mammal selected from the group consisting of a human, a non-human primate, a rat and a mouse.

15. Cancelled.

34. Cancelled.

35. (Currently amended) ~~The method of claim 34,~~
~~wherein~~ A method of promoting wakefulness in a mammal,
comprising administering to a mammal an effective amount of a
PrRP ~~is administered.~~

36. (New) The method of claim 35, wherein said PrRP is a polypeptide comprising SEQ ID NO:23.

37. (New) The method of claim 36, wherein said PrRP is a polypeptide comprising an amino acid sequence selected from SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18.

Inventors: Civelli and Lin
Serial No.: 09/932,161
Filed: August 17, 2001
Page 7

38. (New) The method of claim 37, wherein said PrRP is a polypeptide comprising amino acid sequence SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15.

39. (New) The method of claim 7, wherein the ability of said compound to promote wakefulness is determined by a method selected from the group consisting of EEG measurement, EMG measurement and wake time measurement.

40. (New) The method of claim 7, wherein the ability of said compound to promote wakefulness is determined by administering said compound to a mammal selected from the group consisting of a human, a non-human primate, a rat and a mouse.

41. (New) The method of claim 11, wherein the ability of said compound to promote wakefulness is determined by a method selected from the group consisting of EEG measurement, EMG measurement and wake time measurement.

42. (New) The method of claim 11, wherein the ability of said compound to promote wakefulness is determined by administering said compound to a mammal selected from the group consisting of a human, a non-human primate, a rat and a mouse.